Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Kseniia Bielosludtseva (Dniepropetrovsk, Ukraine), Tetyana Pertseva, Tetyana Kireyeva, Kseniia Bielosludtseva. Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?. Eur Respir J 2015; 46: Suppl. 59, 1847

Member's Comments

No comment yet.

Related content which might interest you: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Modern etiology of severe community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Broad-spectrum antibiotics cannot improve the prognoses of high-risk nursing- and healthcare-associated pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis Source: Eur Respir J 2011; 37: 858-864 Year: 2011 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Direct costs of treating community-acquired pneumonia do not necessarily correlate with clinical severity Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes Year: 2015 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Prior antibiotics and outcomes in patients hospitalized with pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Promising prophylactic means and methods for prevention of community-acquired pneumonia and respiratory infections among servicemen in Russia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Treatment of severe community-acquired pneumonia: new horizons Source: International Congress 2014 – Advances in managing acute respiratory failure Year: 2014